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Objectives
Understanding of progression to antiretroviral therapy (ART) eligibility and associated factors
remains limited. The objectives of this analysis were to determine the time to ART eligibility and
to explore factors associated with disease progression in adults with early HIV infection.
Methods
HIV-infected adults (≥ 18 years old) with CD4 cell count > 500 cells/μl were enrolled in the
study at three primary health care clinics, and a sociodemographic, behavioural and
partnership-level questionnaire was administered. Participants were followed 6-monthly and ART
eligibility was determined using a CD4 cell count threshold of 350 cells/μl. Kaplan − Meier and
Cox proportional hazard regression modelling were used in the analysis.
Results
A total of 206 adults contributed 381 years of follow-up; 79 (38%) reached the ART eligibility
threshold. Median time to ART eligibility was shorter for male patients (12.0 months) than for
female patients (33.9 months). Male sex [adjusted hazard ratio (aHR) 3.13; 95% confidence
interval (CI) 1.82–5.39], residing in a household with food shortage in the previous year (aHR
1.58; 95% CI 0.99–2.54), and taking nutritional supplements in the first 6 months after
enrolment (aHR 2.06; 95% CI 1.11–3.83) were associated with shorter time to ART eligibility.
Compared with reference CD4 cell count ≤ 559 cells/μl, higher CD4 cell count was associated
with longer time to ART eligibility [aHR 0.46 (95% CI 0.25–0.83) for CD4 cell count 560–632
cells/μl; aHR 0.30 (95% CI 0.16–0.57) for CD4 cell count 633–768 cells/μl; and aHR 0.17 (95%
CI 0.08–0.38) for CD4 cell count > 768 cells/μl].
Conclusions
Over one in three adults with CD4 cell count > 500 cells/μl became eligible for ART at a CD4 cell
count threshold of 350 cells/μl over a median of 2 years. The shorter time to ART eligibility in
male patients suggests a possible need for sex-specific pre-ART care and monitoring strategies.
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Introduction
By the end of 2012, in sub-Saharan Africa, an estimated
seven million people of 25 million living with HIV received
antiretroviral therapy (ART) [1], but most HIV-infected
people have either not yet accessed or are not yet eligible
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for ART. With increasing numbers of people diagnosed
early in the course of infection, there is a need for
evidence-based care strategies for this group [1].
Studies in different settings have estimated the time
from HIV-1 seroconversion to reaching a CD4 cell count
threshold of 350 cells/μl for treatment eligibility to be
4–5 years [2,3]. Virological and immunological factors
associated with disease progression have been well char-
acterized [4], but the impact of sociodemographic and
psycho-behavioural factors on disease progression and
time to ART eligibility has been studied less extensively,
particularly in sub-Saharan Africa [5,6]. Understanding
the influence of these factors on HIV disease progression
is important to inform pre-ART care and monitoring
strategies, and for policy decisions concerning the timing
of ART initiation and the use of ART for prevention.
There are few data on time to ART eligibility in those
who present in early HIV infection, although increas-
ing numbers of people are diagnosed and enter care
at higher CD4 cell counts [7]. We used data from a lon-
gitudinal study investigating the impact of ART on the
partnerships and sexual behaviour of HIV-infected indi-
viduals to explore factors associated with disease progres-
sion in adults in the early stages of HIV infection
[8].
Methods
People can access HIV counselling and testing at any
primary health care (PHC) clinic in the Hlabisa sub-district
[9]. Blood is taken for CD4 cell count measurement
immediately after a positive HIV diagnosis. The South
African guidelines for ART eligibility have changed over
the course of this study: CD4 cell count < 200 cells/μl or
World Health Organization (WHO) stage 4 until March
2010; CD4 cell count cut-off < 350 cells/μl for pregnant
women and individuals with active tuberculosis (TB)
disease from April 2010 to August 2011; < 350 cells/μl for
all from August 2011.
Adult (≥ 18 years old) HIV-infected men and nonpreg-
nant women accessing care at three of the PHC clinics
and resident within the Africa Centre Demographic Sur-
veillance Area were potentially eligible for inclusion in
the parent study and were approached for recruitment if
their CD4 cell count was < 200 cells/μl or > 500 cells/μl
[8]. Individuals were asked to consent separately to
linkage of their study data with routine clinical data col-
lected in the HIV programme, specifically clinic attend-
ance history and laboratory test results, and with the
Africa Centre Demographic Information System (ACDIS)
database for their residential history. Sociodemographic,
behavioural and partnership-level data were collected at
enrolment [10]. Study participants were interviewed
6-monthly during routine clinic visits, or where necessary
during home visits or by phone.
The study was approved by the ethics committees of the
University of KwaZulu-Natal (BF083/08), the London
School of Hygiene and Tropical Medicine (5413), and the
KwaZulu-Natal Department of Health.
Individuals with CD4 cell count > 500 cells/μl at enrol-
ment were advised to return 6-monthly for repeat clinical
assessment and CD4 cell count measurement; those with at
least one post-enrolment CD4 cell count result contributed
to the analyses. Characteristics at enrolment for individuals
included in the analyses were compared with those for
individuals who were not using χ2 tests for categorical
variables and Wilcoxon rank sum tests for continuous
variables.
Study recruitment started in January 2009, with
follow-up for 36 months maximum. While many individ-
uals continued to access care from the local HIV pro-
gramme, with additional post-study CD4 cell count results,
only results from tests conducted during study follow-up
were included in this analysis.
Individuals who initiated ART for clinical reasons were
also considered ART-eligible; their ART initiation date was
their eligibility date. ART initiation date was documented
during follow-up or by linkage to the HIV programme
database. Follow-up time for individuals not meeting ART
eligibility criteria was censored at the last CD4 cell count
test date.
Time from study enrolment to ART eligibility, defined
as CD4 cell count < 350 cells/μl, was estimated by
Kaplan − Meier survival analysis. Associations between the
time to ART eligibility and sociodemographic and behav-
ioural factors at enrolment, including ART knowledge,
social capital, social support, relationship characteristics,
and internalized HIV stigma (composite score from
adapted scales), were initially explored using univariable
Cox models [8,10]. We considered all variables that were
significant at univariable level (p value < 0.05) for the
multivariable model. Given previously reported faster
disease progression in men, we explored an interaction
term between CD4 cell count and sex in the final
multivariable model. CD4 cell count was included in the
model as a set of binary indicators representing quartiles
of the baseline distribution: ≤ 559, 560–632, 633–768 and
> 768 cells/μl. The interaction between CD4 cell count and
sex was tested using seven binary indicators to represent
the eight possible categories. A likelihood ratio test of this
interaction was performed and the results compared to a χ2
distribution with three degrees of freedom. The final model
was tested to check that the proportional hazards assump-
tion held.
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Results
Overall, 247 adults had been enrolled by March 2011; 41
(17%) had no post-enrolment CD4 cell count result and did
not contribute to the analyses. These 41 did not differ from
the 206 included by age (P = 0.46), sex (P = 0.56) and
enrolment CD4 cell count (P = 0.69). Thus, 206 adults (14%
male; median age 34 years) contributed 381 years of
follow-up [median 24 months; interquartile range (IQR)
15–30 months] (Table 1), with a median number of CD4 cell
count measurements of 3 (IQR 2–4). CD4 cell count meas-
urement number was not significantly associated with any
factor included in the final model (data not shown).
Overall, 79 (38%) participants became eligible for ART: 75
by CD4 cell count criteria (< 350 cells/μl) and four for
clinical reasons. Among these 79, 41 (52%) started ART
during study follow-up. Based on a CD4 cell count of 500
cells/μl, 129 (63%) would have become eligible for ART.
Univariably, the following were significantly associated
with increased hazard of becoming ART-eligible: male sex
[hazard ratio (HR) 3.13; 95% confidence interval (CI) 1.82–
5.39; P < 0.001], older age [reference ≤ 30 years; 31–40
years, HR 2.16 (95% CI 1.24–3.75); ≥ 41 years, HR 1.55
(95% CI 0.88–2.76); P = 0.02], self-report of household
going without food in the previous 12 months (HR 1.58;
95% CI 0.99–2.54; P = 0.057), higher number of lifetime
partners [reference 1 partner; 2–4 partners, HR 1.33 (95%
CI 0.63–2.83); ≥ 5 partners, HR 2.40 (95% CI 1.08–5.33);
P = 0.032], lower enrolment CD4 cell count [refer-
ence ≤ 559 cells/μl; 560–632 cells/μl, HR 0.73 (95% CI
0.42–1.26); 633–768 cells/μl, HR 0.41 (95% CI 0.22–0.75);
> 768 cells/μl, HR 0.20 (95% CI 0.09–0.45); P < 0.001],
taking nutritional supplements between enrolment and 6
months (HR 2.06; 95% CI 1.11–3.83; P = 0.022) and ever
use of recreational drugs (HR 2.35; 95% CI 1.08–5.15;
P = 0.03) (Table 2). Once adjusted for sex, the number of
lifetime partners and ever use of recreational drugs were no
longer significant. Reported ever alcohol use was 35%
among female patients and 89% among male patients
(P < 0.001), and reported use in the first 6 months of
follow-up was 4% and 43% among female and male
patients, respectively. Neither ever or current alcohol use
was associated with time to ART eligibility. The limited
number of female current drinkers hindered exploration of
associations between time to ART eligibility and alcohol
use in a model including male sex.
Multivariably, lower CD4 cell count at enrolment, being
male, residing in a household with food shortage in the last
year, and nutritional supplement use remained signifi-
cantly associated with increased hazard of meeting ART
eligibility criteria (Table 2). There was no evidence of an
Table 1 Selected characteristics of study participants at enrolment
(n = 206)
Demographic
Sex, female [n (%)] 178 (86)
Age (years) [median (IQR)] 34 (28, 43)
Enrolment CD4 count [n (%)]
≤ 559 cells/μL 53 (26)
560–632 cells/μL 51 (24)
633–768 cells/μL 53 (26)
> 768 cells/μL 49 (24)
Current marital status [n (%)]
Never married 163 (79)
Monogamous marriage 27 (13)
Polygamous marriage 3 (1)
Separated/divorced/widowed 13 (6)
Religion [n (%)]
None 15 (7)
Shembe 39 (19)
Zionist 62 (30)
Western Christian 78 (38)
Other 12 (6)
Education, achieved matriculation or higher [n (%)]a 54 (27)
Parity [median (IQR)]b 2 (2, 4)
Number of lifetime partners [n (%)]
1 28 (14)
2–4 128 (62)
≥5 50 (24)
Number of children [median (IQR)]c 3 (1, 4)
Employment [n (%)]
Currently employed 42 (20)
Ever employed 108 (52)
Receiving social welfare grant [n (%)] 150 (73)
Household unable to afford food in past 12 months [n (%)] 44 (21)
Always resident in Africa Centre DSA [n (%)]d 86 (42)
Stigma score [median (IQR)]e 42 (36,48)
Gender norms score [median (IQR)]f 39 (37, 43)
Taken nutritional supplements in first 6 months of study [n (%)] 23 (11)
Social capital
Neighbour would contribute time for a project [n (%)] 149 (72)
Neighbour would contribute money (R10) for a project [n (%)] 138 (67)
Who would deal with a problem that affected the entire
neighbourhood? [n (%)]
Municipal/district leaders 46 (22)
Each person/household individually or neighbours 14 (7)
Traditional leaders 74 (36)
Traditional and municipal/district leaders would act together 72 (35)
Community groups in neighbourhood, yes [n (%)] 156 (76)
How much can you rely on family/friends if you have a
serious problem? [n (%)]
A little 22 (11)
A lot 179 (87)
Not at all 5 (2)
How often do you spend time with neighbours? [n (%)]
Every day 65 (32)
Several days a week 53 (26)
At least once a fortnight 8 (4)
Once a month 24 (12)
Less than once a month/not at all 56 (27)
aData missing for eight patients.
bFemale patients only; data missing for five patients.
cMale patients only.
dData available for n = 170. In the Africa Centre surveillance system, household mem-
bership is not conditional on residency; an individual can be recorded as a nonresident
household member if they are residing in a household outside the demographic
surveillance area (DSA) but remain socially connected to a household in the DSA.
Changes in residence by individuals and households within the DSA (internal migra-
tion) and into or out of the DSA (external migration) have been documented since
January 2000.
eHIV stigma was measured by a set of 24 questions adapted from Sayles et al.’s 28-item
scale [11]. The questions assessed the individual’s perceived HIV stigma in the com-
munity and internalized HIV stigma. Higher stigma score represents greater HIV-
related stigma. The maximum possible stigma score was 72 and the minimum was 24.
fGender norms were measured by a set of 19 questions from 24 questions developed
by Pulerwitz et al. [12]. Although the Pulerwitz et al. gender norms scale was originally
administered to men only, on review it was considered an appropriate measure of
gender norms for both sexes and administered to men and women. Scores could range
between 19 and 57, with higher scores indicating more equitable gender norms and
lower scores indicating male-dominant gender norms.
DSA, demographic surveillance area; IQR, interquartile range.
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interaction between enrolment CD4 cell count and sex
(P = 0.64). The proportional hazards assumption for the
final model was met (global test P value = 0.81). Median
time to ART eligibility at a CD4 cell count < 350 cells/μl
was 12.0 months (95% CI 8.3–25.1 months) for men, and
33.9 months (95% CI 27.0–36.8 months) for women. The
overall rate of progression to eligibility at a CD4 cell
count < 350 cells/μl was 25.6 per 100 person-years (PY)
(95% CI 20.5–31.9 per 100 PY); rates by year of follow-up
were: 19.3 (95% CI 13.8–26.8) per 100 PY for the first year,
33.6 (95% CI 23.9–47.3) per 100 PY for the second year and
31.8 (95% CI 16.5–61.1) per 100 PY for the third year.
Median time to CD4 cell count < 500 cells/μl for men was
8.3 months (95% CI 6.0–18.6 months) and for women it
was 17.8 months (95% CI 15.9–19.7 months).
Discussion
Just over one in three HIV-infected adults enrolled in HIV
care at an early stage became eligible for ART at a CD4 cell
count < 350 cells/μl. In these HIV-infected people with an
initial CD4 count > 500 cells/μl, progression to ART eli-
gibility was associated with lower baseline CD4 cell count,
male sex, household food insecurity and the personal use
of nutritional supplements.
The study population was predominantly female, con-
sistent with previously reported data [9,13,14], and prob-
ably reflecting higher population-level CD4 cell counts
among women [15] and the different entry points into
HIV care. Previous work did not find any association
between sex and disease progression pre-ART initiation
[4]; however, mortality after ART initiation is consistently
higher in men [16]. Men enrolled in our study may be
incompletely representative of all men with CD4 cell
counts > 500 cells/μl as a consequence of unmeasured
clinical characteristics, but our finding that time to ART
eligibility was significantly shorter for men highlights the
need to develop male-oriented strategies throughout HIV
care [17,18]. Current guidelines recommend ART for all
pregnant females and individuals with TB disease, regard-
less of CD4 cell count, but this was not the case through-
out the study period. We did not estimate the effect this
might have on overall progression to eligibility, although
the estimates would be unlikely to change substantially
as the majority of TB cases and pregnancies are associ-
ated with CD4 cell counts < 350 cells/μl in South Africa
[19,20].
Use of nutritional supplements in the first 6 months of
follow-up may indicate poorer nutritional state and low
body mass index (BMI); similarly, the association with
self-reported household lack of food could also reflect a
link between food insecurity, malnutrition and disease pro-
gression. Other household socioeconomic status indicators
were not associated with time to ART eligibility, suggesting
a specific role of nutrition [21]. However, there is no clear
evidence that macronutrient or micronutrient supplemen-
tation delays HIV disease progression in nonpregnant
adults [22–24]. The complex interplay between HIV and
nutrition means that determining cause and effect relation-
ships is difficult; this was certainly the case in this analysis,
given the study design and the lack of clinical indicators
such as BMI [25]. There was no evidence of an association
between disease progression and any behavioural factors
(including ART knowledge, social capital, social support,
relationship characteristics, and internalized stigma).
Therefore, while interventions to address these issues may
have merit, they should not be expected to delay disease
progression.
Our results are similar to those from a smaller study, also
from KwaZulu-Natal, of female patients monitored from
Table 2 Multivariable Cox proportional hazards regression analysis of factors associated with time to antiretroviral therapy (ART) eligibility
Variable HR 95% CI aHR 95% CI P value
Enrolment CD4 cell count
≤559 cells/μL 1 1
560–632 cells/μL 0.73 0.42–1.28 0.46 0.25–0.83
633–768 cells/μL 0.41 0.22–0.75 0.30 0.16–0.57
>768 cells/μL 0.20 0.09–0.45 0.17 0.08–0.38 <0.001
Sex
Female 1 1
Male 3.13 1.82–5.39 4.00 2.20–7.28 <0.001
Household unable to afford food in past 12 months
No 1 1
Yes 1.58 0.99–2.54 1.58 0.98–2.54 0.062
Taken nutritional supplements in first 6 months of study
No 1 1
Yes 2.06 1.11–3.83 2.38 1.26–4.48 0.007
HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval.
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HIV seroconversion, where 43% reached a CD4 cell count
of < 350 cells/μl within 2 years [26]. Although the
individual-level benefit/risk ratio of commencing ART at
CD4 cell counts > 350 cells/μl has not yet been established
[27,28], international and national guidelines now recom-
mend initiation of ART if the CD4 cell count is < 500
cells/μl [29,30]. Whereas immediate ART may improve
survival in adults with CD4 cell counts > 500 cells/μl, this
benefit might be reversed by potentially high rates of
treatment failure or disengagement from care [31]; the
latter may be more likely as programmes expand [32–34].
In this population, around one in four adults now present
for HIV care with a CD4 cell count > 500 cells/μl [7]; our
finding that most of such adults had not become eligible
during follow-up is consistent with regional natural history
data [35] and suggests that risks of treatment failure and
costs of treatment could be deferred for a considerable
time. However, whether or not this changes the overall
individual benefit/risk ratio and whether there are addi-
tional population-level risks or benefits remain to be seen
[36,37]. Our data would suggest that many individuals will
become eligible within one or two visits in pre-ART care,
especially if visits are less frequent than the recommended
6 months [13]. Education and counselling should empha-
size the importance of retention in care to all patients not
yet requiring ART. Focused messages and systems may be
required to enable retention of men, who may have faster
disease progression and poorer retention in pre-ART care
[13,38].
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